Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
41 hedge funds and large institutions have $1.74M invested in Zynerba Pharmaceuticals, Inc in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 5 closing their positions.
7% less funds holding
Funds holding: 44 → 41 (-3)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
37% less capital invested
Capital invested by funds: $2.75M → $1.74M (-$1.02M)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$43K |
| 2 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$17.8K |
| 3 |
BWP
Bernardo Wealth Planning
Harleysville,
Pennsylvania
|
+$14.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.64K |
| 5 |
JP Morgan Chase
New York
|
+$2.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$118K |
| 2 |
BlackRock
New York
|
-$35.2K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$25.4K |
| 4 |
VF
Virtu Financial
New York
|
-$14K |
| 5 |
HF
HRT Financial
New York
|
-$8K |
ZYNE Hedge Fund Activity: Q2 2023 in Review
41 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2023, worth a combined $1.74M — down 37% from $2.75M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ZYNE and 4 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $43K. The largest seller was Millennium Management, cutting an estimated $118K.
- 41 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2023, down from 44 in Q1 2023.
- Funds reported $1.74M of Zynerba Pharmaceuticals, Inc stock for Q2 2023, down 37% quarter-over-quarter.
- 4 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2023 and 5 closed out, a net change of -1 holder.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2023 was Renaissance Technologies, an estimated $43K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2023 was Millennium Management, an estimated $118K sold.
Based on aggregated 13F filings for Q2 2023.